Soluble Nectin-4 was detected in the serum of patients with metastatic breast cancer and in the supernatants of breast cancer cell lines, with similar immunological and biochemical profiles, in a study demonstrating that the overexpression or silencing of tumor necrosis factor-α convert enzyme (TACE; also known as ADAM-17) enhances or reduces Nectin-4 shedding, respectively. This evidence concerns the gene NECTIN4 and breast carcinoma.